INT136574

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.11
First Reported 2006
Last Reported 2007
Negated 0
Speculated 0
Reported most in Body
Documents 2
Total Number 4
Disease Relevance 1.33
Pain Relevance 1.30

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (TNFAIP3) peptidase activity (TNFAIP3) nucleus (TNFAIP3)
DNA binding (TNFAIP3) ligase activity (TNFAIP3) cytoplasm (TNFAIP3)
TNFAIP3 (Homo sapiens)
Pain Link Frequency Relevance Heat
Adalimumab 302 99.46 Very High Very High Very High
spondylitis 18 89.16 High High
spinal inflammation 356 79.36 Quite High
cINOD 63 54.72 Quite High
Inflammation 54 39.92 Quite Low
backache 9 38.88 Quite Low
imagery 39 35.84 Quite Low
Arthritis 63 5.00 Very Low Very Low Very Low
Pain 45 5.00 Very Low Very Low Very Low
Infliximab 27 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Ankylosis 24 91.40 High High
Seronegative Spondarthritis 381 89.16 High High
Disease Progression 15 82.60 Quite High
Disease 120 76.40 Quite High
Low Back Pain 35 72.56 Quite High
Necrosis 7 70.36 Quite High
Cancer 7 70.00 Quite High
INFLAMMATION 57 39.92 Quite Low
Arthritis 57 5.00 Very Low Very Low Very Low
Pain 24 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
RESULTS: At week 12, 58.2% of adalimumab-treated patients (121 of 208) achieved an ASAS20 response, compared with 20.6% of placebo-treated patients (22 of 107) (P < 0.001).
Regulation (response) of ASAS20
1) Confidence 0.11 Published 2006 Journal Arthritis Rheum. Section Body Doc Link 16802350 Disease Relevance 0.21 Pain Relevance 0
ASAS20 and ASAS40 response was preserved in the adalimumab group and a significant number of placebo patients who elected early escape at 24 weeks achieved an ASAS20 at both 52 and 104 weeks.
Regulation (response) of ASAS20 associated with adalimumab
2) Confidence 0.01 Published 2007 Journal Core Evidence Section Body Doc Link PMC3012440 Disease Relevance 0.20 Pain Relevance 0.39
Secondary outcome measures included the ASAS20 response at week 24 and the ASAS40 response, ASAS5/6 response, and percentage of patients achieving partial remission at weeks 12 and 24.
Regulation (response) of ASAS20
3) Confidence 0.00 Published 2007 Journal Core Evidence Section Body Doc Link PMC3012440 Disease Relevance 0.16 Pain Relevance 0.40
For this small percentage of patients, 50% (three of six) of the adalimumab-treated group achieved an ASAS20 response at week 12 compared with none of the patients receiving placebo.
Regulation (response) of ASAS20 associated with adalimumab
4) Confidence 0.00 Published 2007 Journal Core Evidence Section Body Doc Link PMC3012440 Disease Relevance 0.76 Pain Relevance 0.52

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox